Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
| Autor: | Yun Fan Liaw, W. Bao, Jens Rasenack, Thierry Poynard, Stefan Zeuzem, Jinlin Hou, Maria Buti, Tuan T. Nguyen, Edward Gane, Anuchit Chutaputti, Adrian M. DiBisceglie, Seng Gee Lim, Bruce Belanger, Christopher B. O'Brien, Jidong Jia, Nikolai V. Naoumov |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent Population Pyrimidinones Logistic regression Gastroenterology Antiviral Agents Hepatitis B Chronic Internal medicine Telbivudine medicine Humans Hepatitis B e Antigens education Aged education.field_of_study Hepatology Reverse-transcriptase inhibitor business.industry virus diseases Lamivudine Alanine Transaminase Nucleosides Hepatitis B Middle Aged medicine.disease digestive system diseases Clinical trial Treatment Outcome Immunology DNA Viral Viral disease business medicine.drug Thymidine |
| Zdroj: | Journal of hepatology. 51(1) |
| ISSN: | 1600-0641 |
| Popis: | Background/Aims In the GLOBE trial, telbivudine treatment was identified as a significant, independent predictor of better outcomes at 2years. We analyzed all telbivudine recipients in this trial to determine the predictors of optimal outcomes. Methods The intent-to-treat population comprised 458 HBeAg-positive and 222 HBeAg-negative telbivudine-treated patients. Multivariate logistic regression analyses were employed to evaluate baseline and/or early on-treatment variables. Results Baseline HBV DNA 10 copies/mL, or ALT levels ⩾2× above normal were strong pretreatment predictors for HBeAg-positive, but not for HBeAg-negative patients. However, non-detectable serum HBV DNA at treatment week 24 (TW24) was the strongest predictor for better outcomes for both groups. A combination of pretreatment characteristics plus TW24 response identified subgroups with the best outcomes: (1) HBeAg-positive patients with baseline HBV DNA 10 copies/mL, ALT⩾2× above normal and non-detectable HBV DNA at TW24 achieved at 2years: non-detectable HBV DNA in 89%, HBeAg seroconversion in 52%, telbivudine resistance in 1.8%; and (2) HBeAg-negative patients with baseline HBV DNA 10 copies/mL and non-detectable serum HBV DNA at TW24 achieved at 2years: non-detectable HBV DNA in 91%, telbivudine resistance in 2.3%. Conclusion During telbivudine treatment, non-detectable serum HBV DNA at treatment week 24 is the strongest predictor for optimal outcomes at 2years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect